Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a...
-
Austin, TX, USA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Trans 1, 2 Dichloroethylene Market Size, Trends and Insights By Product Type...
-
Ottawa, Sept. 09, 2025 (GLOBE NEWSWIRE) -- According to a study published by Towards Healthcare, a sister company of Precedence Research, the global life science market size was valued at USD 88.2...
-
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study...
-
Ottawa, Sept. 08, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister firm of Precedence Research, the global progesterone market size was valued at USD 1.52 billion in...
-
Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures,...
-
REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
-
$6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- ...
-
Ra’anana, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related...
-
Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4...